nodes	percent_of_prediction	percent_of_DWPC	metapath
Auranofin—ALB—type 2 diabetes mellitus	0.242	1	CbGaD
Auranofin—ALB—Gliclazide—type 2 diabetes mellitus	0.0891	0.204	CbGbCtD
Auranofin—ALB—Repaglinide—type 2 diabetes mellitus	0.0837	0.192	CbGbCtD
Auranofin—ALB—Rosiglitazone—type 2 diabetes mellitus	0.0699	0.16	CbGbCtD
Auranofin—ALB—Valsartan—type 2 diabetes mellitus	0.0617	0.142	CbGbCtD
Auranofin—ALB—Nateglinide—type 2 diabetes mellitus	0.0574	0.132	CbGbCtD
Auranofin—ALB—Glyburide—type 2 diabetes mellitus	0.0388	0.0889	CbGbCtD
Auranofin—ALB—Losartan—type 2 diabetes mellitus	0.0355	0.0813	CbGbCtD
Auranofin—PRDX5—islet of Langerhans—type 2 diabetes mellitus	0.00402	0.153	CbGeAlD
Auranofin—PRDX5—cardiovascular system—type 2 diabetes mellitus	0.0029	0.111	CbGeAlD
Auranofin—PRDX5—kidney—type 2 diabetes mellitus	0.00284	0.108	CbGeAlD
Auranofin—PRDX5—pancreas—type 2 diabetes mellitus	0.00282	0.107	CbGeAlD
Auranofin—PRDX5—cortex of kidney—type 2 diabetes mellitus	0.00277	0.105	CbGeAlD
Auranofin—PRDX5—adipose tissue—type 2 diabetes mellitus	0.00256	0.0975	CbGeAlD
Auranofin—PRDX5—liver—type 2 diabetes mellitus	0.0018	0.0684	CbGeAlD
Auranofin—IKBKB—cardiovascular system—type 2 diabetes mellitus	0.00172	0.0655	CbGeAlD
Auranofin—IKBKB—cortex of kidney—type 2 diabetes mellitus	0.00164	0.0624	CbGeAlD
Auranofin—IKBKB—adipose tissue—type 2 diabetes mellitus	0.00152	0.0577	CbGeAlD
Auranofin—IKBKB—liver—type 2 diabetes mellitus	0.00106	0.0405	CbGeAlD
Auranofin—ALB—liver—type 2 diabetes mellitus	0.000621	0.0236	CbGeAlD
Auranofin—Thrombocytopenia—Glipizide—type 2 diabetes mellitus	0.000409	0.00257	CcSEcCtD
Auranofin—Constipation—Rosiglitazone—type 2 diabetes mellitus	0.000408	0.00256	CcSEcCtD
Auranofin—Neuropathy peripheral—Orlistat—type 2 diabetes mellitus	0.000403	0.00253	CcSEcCtD
Auranofin—Urticaria—Repaglinide—type 2 diabetes mellitus	0.000401	0.00252	CcSEcCtD
Auranofin—Dysphagia—Irbesartan—type 2 diabetes mellitus	0.000401	0.00252	CcSEcCtD
Auranofin—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.0004	0.00252	CcSEcCtD
Auranofin—Alopecia—Glyburide—type 2 diabetes mellitus	0.0004	0.00251	CcSEcCtD
Auranofin—Abdominal pain—Repaglinide—type 2 diabetes mellitus	0.000399	0.00251	CcSEcCtD
Auranofin—Diarrhoea—Nateglinide—type 2 diabetes mellitus	0.000399	0.00251	CcSEcCtD
Auranofin—Anorexia—Glipizide—type 2 diabetes mellitus	0.000398	0.0025	CcSEcCtD
Auranofin—Neutropenia—Metformin—type 2 diabetes mellitus	0.000397	0.0025	CcSEcCtD
Auranofin—Rash—Tolazamide—type 2 diabetes mellitus	0.000397	0.0025	CcSEcCtD
Auranofin—Rash—Chlorpropamide—type 2 diabetes mellitus	0.000397	0.0025	CcSEcCtD
Auranofin—Dermatitis exfoliative—Ramipril—type 2 diabetes mellitus	0.000397	0.00249	CcSEcCtD
Auranofin—Rash—Linagliptin—type 2 diabetes mellitus	0.000393	0.00247	CcSEcCtD
Auranofin—Dermatitis—Linagliptin—type 2 diabetes mellitus	0.000393	0.00247	CcSEcCtD
Auranofin—Visual impairment—Gliclazide—type 2 diabetes mellitus	0.000392	0.00246	CcSEcCtD
Auranofin—Vomiting—Acarbose—type 2 diabetes mellitus	0.000385	0.00242	CcSEcCtD
Auranofin—Thrombocytopenia—Glimepiride—type 2 diabetes mellitus	0.000382	0.0024	CcSEcCtD
Auranofin—Rash—Acarbose—type 2 diabetes mellitus	0.000381	0.0024	CcSEcCtD
Auranofin—Dermatitis—Acarbose—type 2 diabetes mellitus	0.000381	0.00239	CcSEcCtD
Auranofin—Eye disorder—Gliclazide—type 2 diabetes mellitus	0.00038	0.00239	CcSEcCtD
Auranofin—Urticaria—Rosiglitazone—type 2 diabetes mellitus	0.000379	0.00238	CcSEcCtD
Auranofin—Neutropenia—Irbesartan—type 2 diabetes mellitus	0.000375	0.00236	CcSEcCtD
Auranofin—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.000374	0.00235	CcSEcCtD
Auranofin—Nausea—Tolazamide—type 2 diabetes mellitus	0.000374	0.00235	CcSEcCtD
Auranofin—Eosinophilia—Losartan—type 2 diabetes mellitus	0.000373	0.00235	CcSEcCtD
Auranofin—Anorexia—Glimepiride—type 2 diabetes mellitus	0.000372	0.00234	CcSEcCtD
Auranofin—Neuropathy peripheral—Metformin—type 2 diabetes mellitus	0.000371	0.00233	CcSEcCtD
Auranofin—Vomiting—Nateglinide—type 2 diabetes mellitus	0.000371	0.00233	CcSEcCtD
Auranofin—Rash—Nateglinide—type 2 diabetes mellitus	0.000368	0.00231	CcSEcCtD
Auranofin—Dyspepsia—Glipizide—type 2 diabetes mellitus	0.000368	0.00231	CcSEcCtD
Auranofin—Dermatitis—Nateglinide—type 2 diabetes mellitus	0.000367	0.00231	CcSEcCtD
Auranofin—Anaemia—Glyburide—type 2 diabetes mellitus	0.000364	0.00229	CcSEcCtD
Auranofin—Decreased appetite—Glipizide—type 2 diabetes mellitus	0.000363	0.00228	CcSEcCtD
Auranofin—Angioedema—Glyburide—type 2 diabetes mellitus	0.00036	0.00226	CcSEcCtD
Auranofin—Nausea—Acarbose—type 2 diabetes mellitus	0.000359	0.00226	CcSEcCtD
Auranofin—Constipation—Glipizide—type 2 diabetes mellitus	0.000357	0.00225	CcSEcCtD
Auranofin—Pruritus—Repaglinide—type 2 diabetes mellitus	0.000357	0.00224	CcSEcCtD
Auranofin—Leukopenia—Glyburide—type 2 diabetes mellitus	0.000353	0.00222	CcSEcCtD
Auranofin—Flatulence—Gliclazide—type 2 diabetes mellitus	0.000349	0.00219	CcSEcCtD
Auranofin—Jaundice—Irbesartan—type 2 diabetes mellitus	0.000348	0.00219	CcSEcCtD
Auranofin—Conjunctivitis—Irbesartan—type 2 diabetes mellitus	0.000347	0.00218	CcSEcCtD
Auranofin—Nausea—Nateglinide—type 2 diabetes mellitus	0.000346	0.00218	CcSEcCtD
Auranofin—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.000345	0.00217	CcSEcCtD
Auranofin—Dyspepsia—Glimepiride—type 2 diabetes mellitus	0.000343	0.00216	CcSEcCtD
Auranofin—Dyspepsia—Sitagliptin—type 2 diabetes mellitus	0.000342	0.00215	CcSEcCtD
Auranofin—Gastrointestinal pain—Glipizide—type 2 diabetes mellitus	0.000342	0.00215	CcSEcCtD
Auranofin—Decreased appetite—Glimepiride—type 2 diabetes mellitus	0.000339	0.00213	CcSEcCtD
Auranofin—Decreased appetite—Sitagliptin—type 2 diabetes mellitus	0.000338	0.00212	CcSEcCtD
Auranofin—Pruritus—Rosiglitazone—type 2 diabetes mellitus	0.000338	0.00212	CcSEcCtD
Auranofin—Anorexia—Bromocriptine—type 2 diabetes mellitus	0.000335	0.00211	CcSEcCtD
Auranofin—Agranulocytosis—Irbesartan—type 2 diabetes mellitus	0.000333	0.0021	CcSEcCtD
Auranofin—Constipation—Sitagliptin—type 2 diabetes mellitus	0.000332	0.00209	CcSEcCtD
Auranofin—Urticaria—Glipizide—type 2 diabetes mellitus	0.000332	0.00209	CcSEcCtD
Auranofin—Abdominal pain—Glipizide—type 2 diabetes mellitus	0.00033	0.00208	CcSEcCtD
Auranofin—Alopecia—Valsartan—type 2 diabetes mellitus	0.00033	0.00207	CcSEcCtD
Auranofin—Neuropathy peripheral—Losartan—type 2 diabetes mellitus	0.00033	0.00207	CcSEcCtD
Auranofin—Jaundice—Losartan—type 2 diabetes mellitus	0.000328	0.00206	CcSEcCtD
Auranofin—Anaemia—Gliclazide—type 2 diabetes mellitus	0.000327	0.00205	CcSEcCtD
Auranofin—Conjunctivitis—Losartan—type 2 diabetes mellitus	0.000327	0.00205	CcSEcCtD
Auranofin—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.000326	0.00205	CcSEcCtD
Auranofin—Alopecia—Orlistat—type 2 diabetes mellitus	0.000326	0.00205	CcSEcCtD
Auranofin—Dysphagia—Ramipril—type 2 diabetes mellitus	0.000323	0.00203	CcSEcCtD
Auranofin—Angioedema—Gliclazide—type 2 diabetes mellitus	0.000323	0.00203	CcSEcCtD
Auranofin—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000321	0.00202	CcSEcCtD
Auranofin—Eosinophilia—Ramipril—type 2 diabetes mellitus	0.00032	0.00201	CcSEcCtD
Auranofin—Flatulence—Valsartan—type 2 diabetes mellitus	0.00032	0.00201	CcSEcCtD
Auranofin—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	0.000319	0.002	CcSEcCtD
Auranofin—Rash—Repaglinide—type 2 diabetes mellitus	0.000318	0.002	CcSEcCtD
Auranofin—Dysgeusia—Valsartan—type 2 diabetes mellitus	0.000318	0.002	CcSEcCtD
Auranofin—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000318	0.002	CcSEcCtD
Auranofin—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.000318	0.002	CcSEcCtD
Auranofin—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	0.000318	0.002	CcSEcCtD
Auranofin—Eye disorder—Metformin—type 2 diabetes mellitus	0.000318	0.002	CcSEcCtD
Auranofin—Leukopenia—Gliclazide—type 2 diabetes mellitus	0.000317	0.00199	CcSEcCtD
Auranofin—Flatulence—Orlistat—type 2 diabetes mellitus	0.000316	0.00199	CcSEcCtD
Auranofin—Thrombocytopenia—Glyburide—type 2 diabetes mellitus	0.000315	0.00198	CcSEcCtD
Auranofin—Dysgeusia—Orlistat—type 2 diabetes mellitus	0.000314	0.00198	CcSEcCtD
Auranofin—Agranulocytosis—Losartan—type 2 diabetes mellitus	0.000314	0.00197	CcSEcCtD
Auranofin—Urticaria—Glimepiride—type 2 diabetes mellitus	0.00031	0.00195	CcSEcCtD
Auranofin—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	0.00031	0.00195	CcSEcCtD
Auranofin—Visual impairment—Irbesartan—type 2 diabetes mellitus	0.000309	0.00194	CcSEcCtD
Auranofin—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.000309	0.00194	CcSEcCtD
Auranofin—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.000308	0.00194	CcSEcCtD
Auranofin—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.000307	0.00193	CcSEcCtD
Auranofin—Pancytopenia—Ramipril—type 2 diabetes mellitus	0.000307	0.00193	CcSEcCtD
Auranofin—Anorexia—Glyburide—type 2 diabetes mellitus	0.000306	0.00193	CcSEcCtD
Auranofin—Decreased appetite—Bromocriptine—type 2 diabetes mellitus	0.000306	0.00192	CcSEcCtD
Auranofin—Neutropenia—Ramipril—type 2 diabetes mellitus	0.000302	0.0019	CcSEcCtD
Auranofin—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000301	0.00189	CcSEcCtD
Auranofin—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000301	0.00189	CcSEcCtD
Auranofin—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000301	0.00189	CcSEcCtD
Auranofin—Nausea—Repaglinide—type 2 diabetes mellitus	0.0003	0.00188	CcSEcCtD
Auranofin—Angioedema—Valsartan—type 2 diabetes mellitus	0.000297	0.00187	CcSEcCtD
Auranofin—Pruritus—Glipizide—type 2 diabetes mellitus	0.000296	0.00186	CcSEcCtD
Auranofin—Angioedema—Orlistat—type 2 diabetes mellitus	0.000293	0.00184	CcSEcCtD
Auranofin—Flatulence—Metformin—type 2 diabetes mellitus	0.000292	0.00183	CcSEcCtD
Auranofin—Dysgeusia—Metformin—type 2 diabetes mellitus	0.00029	0.00182	CcSEcCtD
Auranofin—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.000288	0.00181	CcSEcCtD
Auranofin—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000286	0.0018	CcSEcCtD
Auranofin—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000283	0.00178	CcSEcCtD
Auranofin—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000283	0.00178	CcSEcCtD
Auranofin—Neuropathy peripheral—Ramipril—type 2 diabetes mellitus	0.000283	0.00178	CcSEcCtD
Auranofin—Thrombocytopenia—Gliclazide—type 2 diabetes mellitus	0.000283	0.00178	CcSEcCtD
Auranofin—Stomatitis—Ramipril—type 2 diabetes mellitus	0.000281	0.00177	CcSEcCtD
Auranofin—Jaundice—Ramipril—type 2 diabetes mellitus	0.000281	0.00177	CcSEcCtD
Auranofin—Conjunctivitis—Ramipril—type 2 diabetes mellitus	0.00028	0.00176	CcSEcCtD
Auranofin—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.000279	0.00176	CcSEcCtD
Auranofin—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000279	0.00176	CcSEcCtD
Auranofin—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000278	0.00175	CcSEcCtD
Auranofin—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000276	0.00173	CcSEcCtD
Auranofin—Flatulence—Irbesartan—type 2 diabetes mellitus	0.000275	0.00173	CcSEcCtD
Auranofin—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000274	0.00172	CcSEcCtD
Auranofin—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000273	0.00172	CcSEcCtD
Auranofin—Agranulocytosis—Ramipril—type 2 diabetes mellitus	0.000269	0.00169	CcSEcCtD
Auranofin—Alopecia—Losartan—type 2 diabetes mellitus	0.000267	0.00168	CcSEcCtD
Auranofin—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000267	0.00168	CcSEcCtD
Auranofin—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000266	0.00167	CcSEcCtD
Auranofin—Vomiting—Glipizide—type 2 diabetes mellitus	0.000266	0.00167	CcSEcCtD
Auranofin—Rash—Glipizide—type 2 diabetes mellitus	0.000263	0.00166	CcSEcCtD
Auranofin—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000263	0.00165	CcSEcCtD
Auranofin—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000263	0.00165	CcSEcCtD
Auranofin—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	0.00026	0.00163	CcSEcCtD
Auranofin—Flatulence—Losartan—type 2 diabetes mellitus	0.000259	0.00163	CcSEcCtD
Auranofin—Anaemia—Irbesartan—type 2 diabetes mellitus	0.000258	0.00162	CcSEcCtD
Auranofin—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000257	0.00162	CcSEcCtD
Auranofin—Urticaria—Glyburide—type 2 diabetes mellitus	0.000255	0.00161	CcSEcCtD
Auranofin—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000255	0.0016	CcSEcCtD
Auranofin—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000254	0.0016	CcSEcCtD
Auranofin—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000254	0.0016	CcSEcCtD
Auranofin—Anorexia—Valsartan—type 2 diabetes mellitus	0.000253	0.00159	CcSEcCtD
Auranofin—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.00025	0.00157	CcSEcCtD
Auranofin—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000249	0.00157	CcSEcCtD
Auranofin—Nausea—Glipizide—type 2 diabetes mellitus	0.000248	0.00156	CcSEcCtD
Auranofin—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000248	0.00156	CcSEcCtD
Auranofin—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000247	0.00155	CcSEcCtD
Auranofin—Constipation—Gliclazide—type 2 diabetes mellitus	0.000247	0.00155	CcSEcCtD
Auranofin—Rash—Glimepiride—type 2 diabetes mellitus	0.000246	0.00154	CcSEcCtD
Auranofin—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000246	0.00154	CcSEcCtD
Auranofin—Rash—Sitagliptin—type 2 diabetes mellitus	0.000245	0.00154	CcSEcCtD
Auranofin—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000245	0.00154	CcSEcCtD
Auranofin—Anaemia—Losartan—type 2 diabetes mellitus	0.000243	0.00153	CcSEcCtD
Auranofin—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000241	0.00151	CcSEcCtD
Auranofin—Angioedema—Losartan—type 2 diabetes mellitus	0.00024	0.00151	CcSEcCtD
Auranofin—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000236	0.00149	CcSEcCtD
Auranofin—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000236	0.00148	CcSEcCtD
Auranofin—Leukopenia—Losartan—type 2 diabetes mellitus	0.000235	0.00148	CcSEcCtD
Auranofin—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000233	0.00147	CcSEcCtD
Auranofin—Nausea—Glimepiride—type 2 diabetes mellitus	0.000232	0.00146	CcSEcCtD
Auranofin—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000231	0.00145	CcSEcCtD
Auranofin—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000231	0.00145	CcSEcCtD
Auranofin—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000231	0.00145	CcSEcCtD
Auranofin—Anorexia—Metformin—type 2 diabetes mellitus	0.00023	0.00145	CcSEcCtD
Auranofin—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000229	0.00144	CcSEcCtD
Auranofin—Alopecia—Ramipril—type 2 diabetes mellitus	0.000229	0.00144	CcSEcCtD
Auranofin—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000228	0.00143	CcSEcCtD
Auranofin—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000228	0.00143	CcSEcCtD
Auranofin—Pruritus—Glyburide—type 2 diabetes mellitus	0.000227	0.00143	CcSEcCtD
Auranofin—Constipation—Valsartan—type 2 diabetes mellitus	0.000227	0.00143	CcSEcCtD
Auranofin—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000224	0.00141	CcSEcCtD
Auranofin—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000223	0.0014	CcSEcCtD
Auranofin—Rash—Bromocriptine—type 2 diabetes mellitus	0.000222	0.00139	CcSEcCtD
Auranofin—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000222	0.00139	CcSEcCtD
Auranofin—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000221	0.00139	CcSEcCtD
Auranofin—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.00022	0.00138	CcSEcCtD
Auranofin—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000217	0.00137	CcSEcCtD
Auranofin—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000217	0.00136	CcSEcCtD
Auranofin—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000214	0.00135	CcSEcCtD
Auranofin—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000213	0.00134	CcSEcCtD
Auranofin—Urticaria—Valsartan—type 2 diabetes mellitus	0.000211	0.00132	CcSEcCtD
Auranofin—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.00021	0.00132	CcSEcCtD
Auranofin—Decreased appetite—Metformin—type 2 diabetes mellitus	0.00021	0.00132	CcSEcCtD
Auranofin—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.00021	0.00132	CcSEcCtD
Auranofin—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000209	0.00131	CcSEcCtD
Auranofin—Urticaria—Orlistat—type 2 diabetes mellitus	0.000208	0.00131	CcSEcCtD
Auranofin—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000207	0.0013	CcSEcCtD
Auranofin—Constipation—Metformin—type 2 diabetes mellitus	0.000207	0.0013	CcSEcCtD
Auranofin—Angioedema—Ramipril—type 2 diabetes mellitus	0.000206	0.00129	CcSEcCtD
Auranofin—Anorexia—Losartan—type 2 diabetes mellitus	0.000204	0.00129	CcSEcCtD
Auranofin—Vomiting—Glyburide—type 2 diabetes mellitus	0.000204	0.00128	CcSEcCtD
Auranofin—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000204	0.00128	CcSEcCtD
Auranofin—Rash—Glyburide—type 2 diabetes mellitus	0.000203	0.00127	CcSEcCtD
Auranofin—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000203	0.00127	CcSEcCtD
Auranofin—Leukopenia—Ramipril—type 2 diabetes mellitus	0.000202	0.00127	CcSEcCtD
Auranofin—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000201	0.00126	CcSEcCtD
Auranofin—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000198	0.00125	CcSEcCtD
Auranofin—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000198	0.00124	CcSEcCtD
Auranofin—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000197	0.00124	CcSEcCtD
Auranofin—Constipation—Irbesartan—type 2 diabetes mellitus	0.000195	0.00122	CcSEcCtD
Auranofin—Urticaria—Metformin—type 2 diabetes mellitus	0.000192	0.00121	CcSEcCtD
Auranofin—Nausea—Glyburide—type 2 diabetes mellitus	0.000191	0.0012	CcSEcCtD
Auranofin—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000191	0.0012	CcSEcCtD
Auranofin—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000189	0.00119	CcSEcCtD
Auranofin—Pruritus—Valsartan—type 2 diabetes mellitus	0.000188	0.00118	CcSEcCtD
Auranofin—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000186	0.00117	CcSEcCtD
Auranofin—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000186	0.00117	CcSEcCtD
Auranofin—Pruritus—Orlistat—type 2 diabetes mellitus	0.000185	0.00117	CcSEcCtD
Auranofin—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000184	0.00115	CcSEcCtD
Auranofin—Constipation—Losartan—type 2 diabetes mellitus	0.000183	0.00115	CcSEcCtD
Auranofin—Rash—Gliclazide—type 2 diabetes mellitus	0.000182	0.00114	CcSEcCtD
Auranofin—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000182	0.00114	CcSEcCtD
Auranofin—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000181	0.00114	CcSEcCtD
Auranofin—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000181	0.00114	CcSEcCtD
Auranofin—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.00018	0.00113	CcSEcCtD
Auranofin—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	0.00018	0.00113	CcSEcCtD
Auranofin—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000179	0.00113	CcSEcCtD
Auranofin—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000175	0.0011	CcSEcCtD
Auranofin—Anorexia—Ramipril—type 2 diabetes mellitus	0.000175	0.0011	CcSEcCtD
Auranofin—Nausea—Gliclazide—type 2 diabetes mellitus	0.000171	0.00108	CcSEcCtD
Auranofin—Pruritus—Metformin—type 2 diabetes mellitus	0.000171	0.00107	CcSEcCtD
Auranofin—Urticaria—Losartan—type 2 diabetes mellitus	0.00017	0.00107	CcSEcCtD
Auranofin—Abdominal pain—Losartan—type 2 diabetes mellitus	0.00017	0.00107	CcSEcCtD
Auranofin—Vomiting—Valsartan—type 2 diabetes mellitus	0.000169	0.00106	CcSEcCtD
Auranofin—Rash—Valsartan—type 2 diabetes mellitus	0.000167	0.00105	CcSEcCtD
Auranofin—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000167	0.00105	CcSEcCtD
Auranofin—Vomiting—Orlistat—type 2 diabetes mellitus	0.000167	0.00105	CcSEcCtD
Auranofin—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000165	0.00104	CcSEcCtD
Auranofin—Rash—Orlistat—type 2 diabetes mellitus	0.000165	0.00104	CcSEcCtD
Auranofin—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000165	0.00104	CcSEcCtD
Auranofin—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000162	0.00102	CcSEcCtD
Auranofin—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000161	0.00101	CcSEcCtD
Auranofin—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.00016	0.001	CcSEcCtD
Auranofin—Nausea—Valsartan—type 2 diabetes mellitus	0.000158	0.00099	CcSEcCtD
Auranofin—Constipation—Ramipril—type 2 diabetes mellitus	0.000157	0.000988	CcSEcCtD
Auranofin—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000156	0.00098	CcSEcCtD
Auranofin—Nausea—Orlistat—type 2 diabetes mellitus	0.000156	0.000978	CcSEcCtD
Auranofin—Vomiting—Metformin—type 2 diabetes mellitus	0.000154	0.000965	CcSEcCtD
Auranofin—Rash—Metformin—type 2 diabetes mellitus	0.000152	0.000957	CcSEcCtD
Auranofin—Dermatitis—Metformin—type 2 diabetes mellitus	0.000152	0.000956	CcSEcCtD
Auranofin—Pruritus—Losartan—type 2 diabetes mellitus	0.000152	0.000954	CcSEcCtD
Auranofin—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.00015	0.000945	CcSEcCtD
Auranofin—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000147	0.000922	CcSEcCtD
Auranofin—Urticaria—Ramipril—type 2 diabetes mellitus	0.000146	0.000918	CcSEcCtD
Auranofin—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000145	0.000914	CcSEcCtD
Auranofin—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000145	0.000911	CcSEcCtD
Auranofin—Rash—Irbesartan—type 2 diabetes mellitus	0.000144	0.000903	CcSEcCtD
Auranofin—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000144	0.000902	CcSEcCtD
Auranofin—Nausea—Metformin—type 2 diabetes mellitus	0.000143	0.000902	CcSEcCtD
Auranofin—Vomiting—Losartan—type 2 diabetes mellitus	0.000136	0.000857	CcSEcCtD
Auranofin—Nausea—Irbesartan—type 2 diabetes mellitus	0.000135	0.000851	CcSEcCtD
Auranofin—Rash—Losartan—type 2 diabetes mellitus	0.000135	0.00085	CcSEcCtD
Auranofin—Dermatitis—Losartan—type 2 diabetes mellitus	0.000135	0.000849	CcSEcCtD
Auranofin—Pruritus—Ramipril—type 2 diabetes mellitus	0.00013	0.000818	CcSEcCtD
Auranofin—Nausea—Losartan—type 2 diabetes mellitus	0.000127	0.000801	CcSEcCtD
Auranofin—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000126	0.000791	CcSEcCtD
Auranofin—Vomiting—Ramipril—type 2 diabetes mellitus	0.000117	0.000735	CcSEcCtD
Auranofin—Rash—Ramipril—type 2 diabetes mellitus	0.000116	0.000729	CcSEcCtD
Auranofin—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000116	0.000728	CcSEcCtD
Auranofin—Nausea—Ramipril—type 2 diabetes mellitus	0.000109	0.000687	CcSEcCtD
Auranofin—ALB—Platelet activation, signaling and aggregation—IGF1—type 2 diabetes mellitus	2.3e-05	0.000168	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—AKT2—type 2 diabetes mellitus	2.3e-05	0.000168	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—SREBF1—type 2 diabetes mellitus	2.29e-05	0.000168	CbGpPWpGaD
Auranofin—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—AKT1—type 2 diabetes mellitus	2.27e-05	0.000166	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CRHR1—type 2 diabetes mellitus	2.26e-05	0.000166	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—AKT1—type 2 diabetes mellitus	2.26e-05	0.000165	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CTGF—type 2 diabetes mellitus	2.25e-05	0.000165	CbGpPWpGaD
Auranofin—ALB—Hemostasis—NOS1—type 2 diabetes mellitus	2.24e-05	0.000164	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—HMGCR—type 2 diabetes mellitus	2.23e-05	0.000163	CbGpPWpGaD
Auranofin—ALB—Metabolism—G6PC—type 2 diabetes mellitus	2.22e-05	0.000163	CbGpPWpGaD
Auranofin—ALB—Metabolism—PPP1R3C—type 2 diabetes mellitus	2.22e-05	0.000163	CbGpPWpGaD
Auranofin—ALB—Metabolism—ENPP1—type 2 diabetes mellitus	2.22e-05	0.000163	CbGpPWpGaD
Auranofin—ALB—Metabolism—ND1—type 2 diabetes mellitus	2.22e-05	0.000163	CbGpPWpGaD
Auranofin—ALB—Metabolism—HBA2—type 2 diabetes mellitus	2.22e-05	0.000163	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—PRKCB—type 2 diabetes mellitus	2.21e-05	0.000162	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—ICAM1—type 2 diabetes mellitus	2.2e-05	0.000161	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—SERPINE1—type 2 diabetes mellitus	2.18e-05	0.00016	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PTPN1—type 2 diabetes mellitus	2.18e-05	0.00016	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—IRS1—type 2 diabetes mellitus	2.18e-05	0.00016	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—IL6—type 2 diabetes mellitus	2.17e-05	0.000159	CbGpPWpGaD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—AKT1—type 2 diabetes mellitus	2.16e-05	0.000159	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PTPN1—type 2 diabetes mellitus	2.16e-05	0.000158	CbGpPWpGaD
Auranofin—ALB—Metabolism—GCGR—type 2 diabetes mellitus	2.15e-05	0.000157	CbGpPWpGaD
Auranofin—ALB—Hemostasis—RASGRP1—type 2 diabetes mellitus	2.14e-05	0.000157	CbGpPWpGaD
Auranofin—IKBKB—Immune System—RASGRP1—type 2 diabetes mellitus	2.13e-05	0.000156	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—IRS1—type 2 diabetes mellitus	2.09e-05	0.000153	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	2.09e-05	0.000153	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—PIK3R1—type 2 diabetes mellitus	2.08e-05	0.000153	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—EGFR—type 2 diabetes mellitus	2.08e-05	0.000152	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SPRY2—type 2 diabetes mellitus	2.07e-05	0.000152	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	2.07e-05	0.000152	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CYP1A2—type 2 diabetes mellitus	2.07e-05	0.000152	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—PLAT—type 2 diabetes mellitus	2.06e-05	0.000151	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CASP8—type 2 diabetes mellitus	2.05e-05	0.00015	CbGpPWpGaD
Auranofin—ALB—Metabolism—OXCT1—type 2 diabetes mellitus	2.03e-05	0.000149	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYTB—type 2 diabetes mellitus	2.03e-05	0.000149	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—RBP4—type 2 diabetes mellitus	2.02e-05	0.000148	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—GLP1R—type 2 diabetes mellitus	2.02e-05	0.000148	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—AKT2—type 2 diabetes mellitus	2.02e-05	0.000148	CbGpPWpGaD
Auranofin—IKBKB—B Cell Activation—AKT1—type 2 diabetes mellitus	2e-05	0.000147	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CCKAR—type 2 diabetes mellitus	1.98e-05	0.000145	CbGpPWpGaD
Auranofin—ALB—Metabolism—SRD5A1—type 2 diabetes mellitus	1.98e-05	0.000145	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—SLC2A1—type 2 diabetes mellitus	1.97e-05	0.000144	CbGpPWpGaD
Auranofin—ALB—Hemostasis—SOD1—type 2 diabetes mellitus	1.94e-05	0.000142	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—AKT2—type 2 diabetes mellitus	1.94e-05	0.000142	CbGpPWpGaD
Auranofin—ALB—Metabolism—HSD17B3—type 2 diabetes mellitus	1.89e-05	0.000138	CbGpPWpGaD
Auranofin—ALB—Metabolism—ACACA—type 2 diabetes mellitus	1.89e-05	0.000138	CbGpPWpGaD
Auranofin—ALB—Metabolism—STAR—type 2 diabetes mellitus	1.89e-05	0.000138	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—SLC2A4—type 2 diabetes mellitus	1.89e-05	0.000138	CbGpPWpGaD
Auranofin—ALB—Hemostasis—GNB3—type 2 diabetes mellitus	1.88e-05	0.000138	CbGpPWpGaD
Auranofin—ALB—Hemostasis—IGF2—type 2 diabetes mellitus	1.85e-05	0.000135	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—PIK3R1—type 2 diabetes mellitus	1.83e-05	0.000134	CbGpPWpGaD
Auranofin—ALB—Metabolism—CBS—type 2 diabetes mellitus	1.81e-05	0.000133	CbGpPWpGaD
Auranofin—ALB—Metabolism—ABCC8—type 2 diabetes mellitus	1.81e-05	0.000133	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	1.8e-05	0.000132	CbGpPWpGaD
Auranofin—ALB—Hemostasis—APOB—type 2 diabetes mellitus	1.79e-05	0.000131	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IAPP—type 2 diabetes mellitus	1.79e-05	0.000131	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—INSR—type 2 diabetes mellitus	1.78e-05	0.00013	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—BCL2—type 2 diabetes mellitus	1.76e-05	0.000129	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—PIK3R1—type 2 diabetes mellitus	1.76e-05	0.000129	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TRPC6—type 2 diabetes mellitus	1.74e-05	0.000128	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC5A2—type 2 diabetes mellitus	1.74e-05	0.000128	CbGpPWpGaD
Auranofin—ALB—Metabolism—COX2—type 2 diabetes mellitus	1.74e-05	0.000128	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—AGTR2—type 2 diabetes mellitus	1.73e-05	0.000127	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—RELA—type 2 diabetes mellitus	1.72e-05	0.000126	CbGpPWpGaD
Auranofin—ALB—Metabolism—NCOA6—type 2 diabetes mellitus	1.71e-05	0.000125	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PPARGC1A—type 2 diabetes mellitus	1.71e-05	0.000125	CbGpPWpGaD
Auranofin—ALB—Metabolism—HSD11B1—type 2 diabetes mellitus	1.68e-05	0.000123	CbGpPWpGaD
Auranofin—ALB—Metabolism—UCP3—type 2 diabetes mellitus	1.68e-05	0.000123	CbGpPWpGaD
Auranofin—ALB—Metabolism—UCP2—type 2 diabetes mellitus	1.68e-05	0.000123	CbGpPWpGaD
Auranofin—IKBKB—Immune System—AGER—type 2 diabetes mellitus	1.67e-05	0.000122	CbGpPWpGaD
Auranofin—IKBKB—Immune System—ADCY5—type 2 diabetes mellitus	1.66e-05	0.000122	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.66e-05	0.000122	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—RELA—type 2 diabetes mellitus	1.65e-05	0.000121	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—APOB—type 2 diabetes mellitus	1.63e-05	0.000119	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—GNB3—type 2 diabetes mellitus	1.63e-05	0.000119	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IL6—type 2 diabetes mellitus	1.63e-05	0.000119	CbGpPWpGaD
Auranofin—ALB—Hemostasis—CD36—type 2 diabetes mellitus	1.63e-05	0.000119	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—HMOX1—type 2 diabetes mellitus	1.62e-05	0.000119	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.61e-05	0.000118	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.61e-05	0.000118	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CD36—type 2 diabetes mellitus	1.61e-05	0.000118	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PPP2CA—type 2 diabetes mellitus	1.6e-05	0.000118	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—AVP—type 2 diabetes mellitus	1.6e-05	0.000118	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—IL6—type 2 diabetes mellitus	1.6e-05	0.000117	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PPP2CA—type 2 diabetes mellitus	1.59e-05	0.000117	CbGpPWpGaD
Auranofin—ALB—Metabolism—PCK1—type 2 diabetes mellitus	1.58e-05	0.000116	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.57e-05	0.000115	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.56e-05	0.000114	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—LPL—type 2 diabetes mellitus	1.56e-05	0.000114	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—APOB—type 2 diabetes mellitus	1.55e-05	0.000114	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—SRC—type 2 diabetes mellitus	1.54e-05	0.000113	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.54e-05	0.000112	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.53e-05	0.000112	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.53e-05	0.000112	CbGpPWpGaD
Auranofin—IKBKB—Immune System—C3—type 2 diabetes mellitus	1.53e-05	0.000112	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—GPX1—type 2 diabetes mellitus	1.52e-05	0.000111	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.51e-05	0.000111	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—VEGFA—type 2 diabetes mellitus	1.5e-05	0.00011	CbGpPWpGaD
Auranofin—ALB—Hemostasis—MMP1—type 2 diabetes mellitus	1.48e-05	0.000109	CbGpPWpGaD
Auranofin—ALB—Metabolism—HK1—type 2 diabetes mellitus	1.48e-05	0.000108	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CD36—type 2 diabetes mellitus	1.48e-05	0.000108	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—AKT1—type 2 diabetes mellitus	1.47e-05	0.000108	CbGpPWpGaD
Auranofin—IKBKB—Immune System—BCL2L1—type 2 diabetes mellitus	1.46e-05	0.000107	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CRP—type 2 diabetes mellitus	1.45e-05	0.000106	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IRS2—type 2 diabetes mellitus	1.45e-05	0.000106	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—NFKB1—type 2 diabetes mellitus	1.45e-05	0.000106	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—ADCY5—type 2 diabetes mellitus	1.45e-05	0.000106	CbGpPWpGaD
Auranofin—ALB—Hemostasis—CALM1—type 2 diabetes mellitus	1.44e-05	0.000105	CbGpPWpGaD
Auranofin—ALB—Metabolism—LPA—type 2 diabetes mellitus	1.43e-05	0.000105	CbGpPWpGaD
Auranofin—ALB—Metabolism—GCKR—type 2 diabetes mellitus	1.43e-05	0.000105	CbGpPWpGaD
Auranofin—ALB—Metabolism—HSD3B2—type 2 diabetes mellitus	1.43e-05	0.000105	CbGpPWpGaD
Auranofin—ALB—Metabolism—KCNJ11—type 2 diabetes mellitus	1.43e-05	0.000105	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CALM1—type 2 diabetes mellitus	1.43e-05	0.000105	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.42e-05	0.000104	CbGpPWpGaD
Auranofin—ALB—Hemostasis—APOA1—type 2 diabetes mellitus	1.42e-05	0.000104	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—GCG—type 2 diabetes mellitus	1.4e-05	0.000102	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.4e-05	0.000102	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—NFKB1—type 2 diabetes mellitus	1.39e-05	0.000102	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—TGFB1—type 2 diabetes mellitus	1.38e-05	0.000101	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.38e-05	0.000101	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PPARA—type 2 diabetes mellitus	1.38e-05	0.000101	CbGpPWpGaD
Auranofin—ALB—Metabolism—ALDOB—type 2 diabetes mellitus	1.37e-05	0.0001	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.37e-05	0.0001	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—SRC—type 2 diabetes mellitus	1.35e-05	9.91e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PRKCB—type 2 diabetes mellitus	1.35e-05	9.9e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PRKCB—type 2 diabetes mellitus	1.34e-05	9.83e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—ICAM1—type 2 diabetes mellitus	1.34e-05	9.79e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—NOS2—type 2 diabetes mellitus	1.34e-05	9.79e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—AGT—type 2 diabetes mellitus	1.33e-05	9.76e-05	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	1.31e-05	9.58e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—APOE—type 2 diabetes mellitus	1.31e-05	9.56e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—SRC—type 2 diabetes mellitus	1.3e-05	9.52e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—APOA1—type 2 diabetes mellitus	1.29e-05	9.45e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GLP1R—type 2 diabetes mellitus	1.28e-05	9.34e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IRS1—type 2 diabetes mellitus	1.27e-05	9.29e-05	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	1.23e-05	8.99e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.22e-05	8.91e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.21e-05	8.83e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CASP8—type 2 diabetes mellitus	1.2e-05	8.76e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC2A2—type 2 diabetes mellitus	1.19e-05	8.72e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.19e-05	8.71e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—AVP—type 2 diabetes mellitus	1.19e-05	8.71e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—EGFR—type 2 diabetes mellitus	1.19e-05	8.69e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—IGF1—type 2 diabetes mellitus	1.18e-05	8.68e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—AKT2—type 2 diabetes mellitus	1.18e-05	8.67e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.18e-05	8.67e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.18e-05	8.63e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—AKT2—type 2 diabetes mellitus	1.17e-05	8.6e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—MTR—type 2 diabetes mellitus	1.17e-05	8.54e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CPT1A—type 2 diabetes mellitus	1.17e-05	8.54e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—APOB—type 2 diabetes mellitus	1.15e-05	8.42e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.14e-05	8.38e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NAMPT—type 2 diabetes mellitus	1.14e-05	8.38e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—EGFR—type 2 diabetes mellitus	1.14e-05	8.34e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PPARG—type 2 diabetes mellitus	1.14e-05	8.33e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—LIPC—type 2 diabetes mellitus	1.14e-05	8.32e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—HBA1—type 2 diabetes mellitus	1.14e-05	8.32e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GCK—type 2 diabetes mellitus	1.14e-05	8.32e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.13e-05	8.28e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP11A1—type 2 diabetes mellitus	1.13e-05	8.27e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—SERPINE1—type 2 diabetes mellitus	1.13e-05	8.24e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC9A1—type 2 diabetes mellitus	1.11e-05	8.12e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—LPL—type 2 diabetes mellitus	1.1e-05	8.04e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CETP—type 2 diabetes mellitus	1.1e-05	8.03e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.07e-05	7.87e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—PIK3R1—type 2 diabetes mellitus	1.07e-05	7.87e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—NOS3—type 2 diabetes mellitus	1.07e-05	7.87e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—PIK3R1—type 2 diabetes mellitus	1.07e-05	7.81e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.03e-05	7.54e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—BCL2—type 2 diabetes mellitus	1.03e-05	7.52e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PSMD6—type 2 diabetes mellitus	1.02e-05	7.47e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SREBF1—type 2 diabetes mellitus	1.02e-05	7.47e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SNAP25—type 2 diabetes mellitus	1.02e-05	7.47e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.01e-05	7.4e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—RELA—type 2 diabetes mellitus	1e-05	7.35e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CTGF—type 2 diabetes mellitus	1e-05	7.33e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—HMGCR—type 2 diabetes mellitus	9.92e-06	7.26e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—C3—type 2 diabetes mellitus	9.88e-06	7.24e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	9.78e-06	7.16e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ADRA2A—type 2 diabetes mellitus	9.7e-06	7.11e-05	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	9.58e-06	7.02e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.42e-06	6.9e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.4e-06	6.88e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—AGT—type 2 diabetes mellitus	9.39e-06	6.88e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP2E1—type 2 diabetes mellitus	9.32e-06	6.83e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CALM1—type 2 diabetes mellitus	9.23e-06	6.76e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP1A2—type 2 diabetes mellitus	9.22e-06	6.75e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC2A1—type 2 diabetes mellitus	9.22e-06	6.75e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—APOE—type 2 diabetes mellitus	9.2e-06	6.74e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—LEP—type 2 diabetes mellitus	9.2e-06	6.74e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—IL6—type 2 diabetes mellitus	9.12e-06	6.68e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—APOA1—type 2 diabetes mellitus	9.09e-06	6.66e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP3A4—type 2 diabetes mellitus	8.99e-06	6.58e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	8.94e-06	6.55e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GCG—type 2 diabetes mellitus	8.84e-06	6.47e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—SLC2A4—type 2 diabetes mellitus	8.84e-06	6.47e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.67e-06	6.35e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—NFKB1—type 2 diabetes mellitus	8.46e-06	6.2e-05	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—AKT1—type 2 diabetes mellitus	8.41e-06	6.16e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.2e-06	6.01e-05	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—AKT1—type 2 diabetes mellitus	8.08e-06	5.92e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—SRC—type 2 diabetes mellitus	7.95e-06	5.82e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—SRC—type 2 diabetes mellitus	7.88e-06	5.77e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—INS—type 2 diabetes mellitus	7.86e-06	5.75e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—VEGFA—type 2 diabetes mellitus	7.74e-06	5.67e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.73e-06	5.66e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.62e-06	5.58e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GNB3—type 2 diabetes mellitus	7.62e-06	5.58e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.6e-06	5.57e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.59e-06	5.56e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—HMOX1—type 2 diabetes mellitus	7.58e-06	5.55e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CAT—type 2 diabetes mellitus	7.48e-06	5.48e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—APOB—type 2 diabetes mellitus	7.26e-06	5.32e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.22e-06	5.29e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	7.1e-06	5.2e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	7.07e-06	5.17e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—LPL—type 2 diabetes mellitus	6.94e-06	5.08e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—EGFR—type 2 diabetes mellitus	6.91e-06	5.06e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.89e-06	5.05e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.89e-06	5.05e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	6.79e-06	4.97e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—GPX1—type 2 diabetes mellitus	6.77e-06	4.96e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CD36—type 2 diabetes mellitus	6.59e-06	4.83e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	6.51e-06	4.77e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—RELA—type 2 diabetes mellitus	6.49e-06	4.75e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	6.24e-06	4.57e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PPARA—type 2 diabetes mellitus	6.13e-06	4.49e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—AGT—type 2 diabetes mellitus	5.93e-06	4.35e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.85e-06	4.28e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—CALM1—type 2 diabetes mellitus	5.83e-06	4.27e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—APOE—type 2 diabetes mellitus	5.81e-06	4.26e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—APOA1—type 2 diabetes mellitus	5.75e-06	4.21e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.53e-06	4.05e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.47e-06	4.01e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL6—type 2 diabetes mellitus	5.31e-06	3.89e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SRC—type 2 diabetes mellitus	5.1e-06	3.73e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PPARG—type 2 diabetes mellitus	5.06e-06	3.71e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—INS—type 2 diabetes mellitus	4.97e-06	3.64e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.96e-06	3.64e-05	CbGpPWpGaD
Auranofin—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	4.94e-06	3.62e-05	CbGpPWpGaD
Auranofin—IKBKB—Immune System—AKT1—type 2 diabetes mellitus	4.9e-06	3.59e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.56e-06	3.34e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.47e-06	3.27e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	4.36e-06	3.19e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—NOS3—type 2 diabetes mellitus	4.36e-06	3.19e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	3.98e-06	2.92e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IL6—type 2 diabetes mellitus	3.43e-06	2.51e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.17e-06	2.32e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—AKT1—type 2 diabetes mellitus	2e-06	1.47e-05	CbGpPWpGaD
